A novel method for imaging the pharmacological effects of antibiotic treatment on Clostridium difficile.
Clostridium difficile is a significant cause of nosocomial-acquired infection that results in severe diarrhea and can lead to mortality. Treatment options for C. difficile infection (CDI) are limited, however, new antibiotics are being developed. Current methods for determining efficacy of experimental antibiotics on C. difficile involve antibiotic killing rates and do not give insight into the drug's pharmacologic effects. Considering this, we hypothesized that by using scanning electron microscopy (SEM) in tandem to drug killing curves, we would be able to determine efficacy and visualize the phenotypic response to drug treatment. To test this hypothesis, supraMIC kill curves were conducted using vancomycin, metronidazole, fidaxomicin, and ridinilazole. Following collection, cells were either plated or imaged using a scanning electron microscope (SEM). Consistent with previous reports, we found that the tested antibiotics had significant bactericidal activity at supraMIC concentrations. By SEM imaging and using a semi-automatic pipeline for image analysis, we were able to determine that vancomycin and to a lesser extent fidaxomicin and ridinilazole significantly affected the cell wall, whereas metronidazole, fidaxomicin, and ridinilazole had significant effects on cell length suggesting a metabolic effect. While the phenotypic response to drug treatment has not been documented previously in this manner, the results observed are consistent with the drug's mechanism of action. These techniques demonstrate the versatility and reliability of imaging and measurements that could be applied to other experimental compounds. We believe the strategies laid out here are vital for characterizing new antibiotics in development for treating CDI.
Department of Pharmacy Practice and Translational Research, Houston, TX, USA.
Bradley T
BT
Endres
Department of Pharmacy Practice and Translational Research, Houston, TX, USA.
Eugénie
E
Bassères
Department of Computer Science, University of Houston, Houston, TX, USA.
Ali
A
Memariani
Department of Electrical and Computer Engineering, Houston, TX, USA.
Long
L
Chang
Department of Pharmacy Practice and Translational Research, Houston, TX, USA.
M Jahangir
MJ
Alam
Summit Therapeutics, Abingdon, Oxfordshire, UK.
Richard J
RJ
Vickers
Department of Computer Science, University of Houston, Houston, TX, USA.
Ioannis A
IA
Kakadiaris
Department of Pharmacy Practice and Translational Research, Houston, TX, USA. Electronic address: kgarey@central.uh.edu.
Kevin W
KW
Garey
D000362:Agar / Q000737:chemistry; D000617:Aminoglycosides / Q000494:pharmacology; D000900:Anti-Bacterial Agents / Q000494:pharmacology*; D002473:Cell Wall / Q000187:drug effects* / Q000648:ultrastructure; D016360:Clostridioides difficile / Q000187:drug effects* / Q000648:ultrastructure; D003470:Culture Media / Q000737:chemistry; D000077732:Fidaxomicin; D008795:Metronidazole / Q000494:pharmacology; D008826:Microbial Sensitivity Tests; D008855:Microscopy, Electron, Scanning; D061848:Optical Imaging / Q000379:methods*; D014640:Vancomycin / Q000494:pharmacology
D000617:Aminoglycosides; D000900:Anti-Bacterial Agents; D003470:Culture Media; D008795:Metronidazole; D014640:Vancomycin; D000362:Agar; D000077732:Fidaxomicin
Antibiotics; Clostridium difficile; Fidaxomicin; Metronidazole; Ridinilazole; Scanning electron microscopy; Vancomycin